Troy Edward Wilson sold $78k of PBYI
director at PUMA BIOTECHNOLOGY, INC.. 10,800 shares at an average of $7.20, traded Jun 12, 2026, filed Jun 15, 2026.
Score components
- +15RoleDirector
- +9Trade size$78k at market
- +5Share of holdings soldSold 15% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-020709, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | AGrant or award Common Stock10b5-1 | +27,000 | $0.00 | $0 | 70,550 | Jun 15, 2026 |
| Jun 12, 2026 | SOpen-market sale Common Stock10b5-1 | -10,800 | $7.20 | $78k | 59,750 | Jun 15, 2026 |
Related signals
Other insiders at PUMA BIOTECHNOLOGY, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | PUMA BIOTECHNOLOGY, INC. | Alessandra Cesano director | $567k 62,150 shares | -52% | |
| 9Weak | PUMA BIOTECHNOLOGY, INC. | Troy Edward Wilson director | $46k 5,000 shares | -8% | |
| 35Weak | PUMA BIOTECHNOLOGY, INC. | Alan H Auerbach President and CEO | $364k 44,058 shares | -1% | |
| 18Weak | PUMA BIOTECHNOLOGY, INC. | Douglas M Hunt See Remarks | $70k 8,460 shares | -4% | |
| 26Weak | PUMA BIOTECHNOLOGY, INC. | Maximo F Nougues Chief Financial Officer | $78k 9,386 shares | -4% | |
| 24Weak | PUMA BIOTECHNOLOGY, INC. | Allison Dorval director | $84k 11,610 shares | -11% | |
| 31Weak | PUMA BIOTECHNOLOGY, INC. | Jay M Moyes director | $159k 22,000 shares | -27% | |
| 42Moderate | PUMA BIOTECHNOLOGY, INC. | Adrian Senderowicz director | $194k 27,000 shares | -50% | |
| 17Weak | PUMA BIOTECHNOLOGY, INC. | Brian M Stuglik director | $58k 8,100 shares | -7% | |
| 32Weak | PUMA BIOTECHNOLOGY, INC. | Alan H Auerbach President and CEO | $205k 34,950 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.